Santa barbara, Ca., USA - November 19, 2010, Santa barbara, Ca., USA - CytomX Therapeutics, a biotechnology company, announced the appointment of Mark Rolfe as chief scientific officer.
Article continues below
Dr. Rolfe brings more than 20 years’ experience in oncology drug discovery and development, working with companies including Abbott Laboratories’ Facet Biotech and Millennium Pharmaceuticals.
Dr. Rolfe has extensive experience discovering kinase inhibitors, inhibitors of the ubiquitin proteasome system and novel cancer antibodies. Most recently, he was chief scientific officer and interim chief medical officer at Facet Biotech, recently acquired by Abbott Laboratories, where he was developing strategies for translational medicine and oncology focused discovery efforts.
Prior to Facet, Dr. Rolfe spent 10 years at Millennium Pharmaceuticals serving in a number of positions, including vice president, oncology biology. Dr. Rolfe has published 43 scientific articles and book chapters, has presented his work at major international scientific congresses and has been a reviewer for a wide range of scientific publications including Nature Medicine, Molecular and Cellular Biology and PNAS.
Dr. Rolfe received his B.A. from Oxford University, his Ph.D. from the National Institute for Medical Research and completed Post-Doctoral Fellowships at the ICRF in London and Columbia University in New York.
The company has also appointed Henry Lowman, Ph.D., to the position of vice president of research. Dr. Lowman joins CytomX after 20 years with Genentech
Dr. Lowman joins CytomX from NGM Biopharmaceuticals, where he was director of protein sciences. Prior to then, Lowman spent 20 years in research and development at Genentech, Inc., where he began as an NIH Postdoctoral Fellow, and most recently served as director of the antibody engineering department.
Dr. Lowman's focus has been in the areas of structure-based protein design, structure-function analysis and molecular diversity techniques, which he has applied in several therapeutic development projects. He is an inventor on more than 50 issued patents and currently serves as an editorial board member for the antibody journal mAbs. ■